Thorough QT Study to Evaluate the Effects of Single Doses of Vicadrostat on Cardiac Safety Parameters in Healthy Male and Female Subjects (a Randomized, Placebo-controlled, Double-blind, Five-period Crossover Study With Open-label Moxifloxacin as Positive Control)
Latest Information Update: 15 Apr 2026
At a glance
- Drugs Vicadrostat (Primary)
- Indications Cardiovascular disorders; Heart failure; Hypertension; Renal failure; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International
Most Recent Events
- 06 Apr 2026 New trial record